181 related articles for article (PubMed ID: 27599351)
1. Application of a pharmacokinetic/pharmacogenetic approach to assess the nicotine metabolic profile of smokers in the real-life setting.
Fogli S; Saba A; Del Re M; Pistelli F; Aquilini F; Zucchi R; Palla A; Breschi MC; Carrozzi L; Danesi R
J Pharm Biomed Anal; 2016 Nov; 131():208-213. PubMed ID: 27599351
[TBL] [Abstract][Full Text] [Related]
2. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking.
Malaiyandi V; Goodz SD; Sellers EM; Tyndale RF
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1812-9. PubMed ID: 17035386
[TBL] [Abstract][Full Text] [Related]
3. Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application.
Levi M; Dempsey DA; Benowitz NL; Sheiner LB
J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):23-34. PubMed ID: 17206525
[TBL] [Abstract][Full Text] [Related]
4. Genetic determinants of cytochrome P450 2A6 activity and biomarkers of tobacco smoke exposure in relation to risk of lung cancer development in the Shanghai cohort study.
Yuan JM; Nelson HH; Butler LM; Carmella SG; Wang R; Kuriger-Laber JK; Adams-Haduch J; Hecht SS; Gao YT; Murphy SE
Int J Cancer; 2016 May; 138(9):2161-71. PubMed ID: 26662855
[TBL] [Abstract][Full Text] [Related]
5. Determination of the nicotine metabolites cotinine and trans-3'-hydroxycotinine in biologic fluids of smokers and non-smokers using liquid chromatography-tandem mass spectrometry: biomarkers for tobacco smoke exposure and for phenotyping cytochrome P450 2A6 activity.
Jacob P; Yu L; Duan M; Ramos L; Yturralde O; Benowitz NL
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Feb; 879(3-4):267-76. PubMed ID: 21208832
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity.
El-Boraie A; Taghavi T; Chenoweth MJ; Fukunaga K; Mushiroda T; Kubo M; Lerman C; Nollen NL; Benowitz NL; Tyndale RF
Addict Biol; 2020 Jan; 25(1):e12741. PubMed ID: 30815984
[TBL] [Abstract][Full Text] [Related]
7. An association of CYP2A6 genotype and smoking topography.
Strasser AA; Malaiyandi V; Hoffmann E; Tyndale RF; Lerman C
Nicotine Tob Res; 2007 Apr; 9(4):511-8. PubMed ID: 17454707
[TBL] [Abstract][Full Text] [Related]
8. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.
Dempsey D; Tutka P; Jacob P; Allen F; Schoedel K; Tyndale RF; Benowitz NL
Clin Pharmacol Ther; 2004 Jul; 76(1):64-72. PubMed ID: 15229465
[TBL] [Abstract][Full Text] [Related]
9. Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer.
Tanner JA; Henderson JA; Buchwald D; Howard BV; Nez Henderson P; Tyndale RF
Pharmacogenet Genomics; 2017 May; 27(5):169-178. PubMed ID: 28181923
[TBL] [Abstract][Full Text] [Related]
10. Impact of Genetic Variants in the Nicotine Metabolism Pathway on Nicotine Metabolite Levels in Smokers.
Perez-Paramo YX; Watson CJW; Chen G; Thomas CE; Adams-Haduch J; Wang R; Khor CC; Koh WP; Nelson HH; Yuan JM; Lazarus P
Cancer Epidemiol Biomarkers Prev; 2023 Jan; 32(1):54-65. PubMed ID: 36252563
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences.
Chenoweth MJ; Ware JJ; Zhu AZX; Cole CB; Cox LS; Nollen N; Ahluwalia JS; Benowitz NL; Schnoll RA; Hawk LW; Cinciripini PM; George TP; Lerman C; Knight J; Tyndale RF;
Addiction; 2018 Mar; 113(3):509-523. PubMed ID: 28921760
[TBL] [Abstract][Full Text] [Related]
12. Genetic determinants of CYP2A6 activity across racial/ethnic groups with different risks of lung cancer and effect on their smoking intensity.
Park SL; Tiirikainen MI; Patel YM; Wilkens LR; Stram DO; Le Marchand L; Murphy SE
Carcinogenesis; 2016 Mar; 37(3):269-279. PubMed ID: 26818358
[TBL] [Abstract][Full Text] [Related]
13. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation.
Lerman C; Tyndale R; Patterson F; Wileyto EP; Shields PG; Pinto A; Benowitz N
Clin Pharmacol Ther; 2006 Jun; 79(6):600-8. PubMed ID: 16765148
[TBL] [Abstract][Full Text] [Related]
14. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy.
Malaiyandi V; Lerman C; Benowitz NL; Jepson C; Patterson F; Tyndale RF
Mol Psychiatry; 2006 Apr; 11(4):400-9. PubMed ID: 16402128
[TBL] [Abstract][Full Text] [Related]
15. Enhanced nicotine metabolism in HIV-1-positive smokers compared with HIV-negative smokers: simultaneous determination of nicotine and its four metabolites in their plasma using a simple and sensitive electrospray ionization liquid chromatography-tandem mass spectrometry technique.
Earla R; Ande A; McArthur C; Kumar A; Kumar S
Drug Metab Dispos; 2014 Feb; 42(2):282-93. PubMed ID: 24301609
[TBL] [Abstract][Full Text] [Related]
16. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers.
Ho MK; Mwenifumbo JC; Al Koudsi N; Okuyemi KS; Ahluwalia JS; Benowitz NL; Tyndale RF
Clin Pharmacol Ther; 2009 Jun; 85(6):635-43. PubMed ID: 19279561
[TBL] [Abstract][Full Text] [Related]
17. Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers.
Chenoweth MJ; Novalen M; Hawk LW; Schnoll RA; George TP; Cinciripini PM; Lerman C; Tyndale RF
Cancer Epidemiol Biomarkers Prev; 2014 Sep; 23(9):1773-82. PubMed ID: 25012994
[TBL] [Abstract][Full Text] [Related]
18. Genome-Wide Association of the Laboratory-Based Nicotine Metabolite Ratio in Three Ancestries.
Baurley JW; Edlund CK; Pardamean CI; Conti DV; Krasnow R; Javitz HS; Hops H; Swan GE; Benowitz NL; Bergen AW
Nicotine Tob Res; 2016 Sep; 18(9):1837-1844. PubMed ID: 27113016
[TBL] [Abstract][Full Text] [Related]
19. Transferability of Ancestry-Specific and Cross-Ancestry CYP2A6 Activity Genetic Risk Scores in African and European Populations.
El-Boraie A; Chenoweth MJ; Pouget JG; Benowitz NL; Fukunaga K; Mushiroda T; Kubo M; Nollen NL; Sanderson Cox L; Lerman C; Knight J; Tyndale RF
Clin Pharmacol Ther; 2021 Oct; 110(4):975-985. PubMed ID: 33300144
[TBL] [Abstract][Full Text] [Related]
20. A fully validated LC-MS/MS method for simultaneous determination of nicotine and its metabolite cotinine in human serum and its application to a pharmacokinetic study after using nicotine transdermal delivery systems with standard heat application in adult smokers.
Abdallah IA; Hammell DC; Stinchcomb AL; Hassan HE
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 May; 1020():67-77. PubMed ID: 27023159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
